Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR. 15 Aug, 2022 | 11:44h | UTC Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR – Journal of Clinical Oncology Original Study: Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study – Journal of Clinical Oncology